Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and immunogenicity of a single-dose omicron-containing COVID-19 vaccination in adolescents: an open-label, single-arm, phase 2/3 trial.
Figueroa AL, Torres D, Reyes-Acuna C, Matherne P, Yeakey A, Deng W, Xu W, Sigal Y, Chambers G, Olsen M, Girard B, Miller JM, Das R, Priddy F. Figueroa AL, et al. Among authors: yeakey a. Lancet Infect Dis. 2024 Sep 24:S1473-3099(24)00501-2. doi: 10.1016/S1473-3099(24)00501-2. Online ahead of print. Lancet Infect Dis. 2024. PMID: 39332418
A review of the immunogenicity and safety of booster doses of omicron variant-containing mRNA-1273 COVID-19 vaccines in adults and children.
Priddy F, Chalkias S, Essink B, Whatley J, Brosz A, Lee IT, Feng J, Tracy L, Deng W, Zhou W, Zhou H, Dixit A, Schnyder-Ghamloush S, Girard B, de Windt E, Yeakey A, Miller J, Das R, Kuter BJ. Priddy F, et al. Among authors: yeakey a. Expert Rev Vaccines. 2024 Jan-Dec;23(1):862-878. doi: 10.1080/14760584.2024.2397026. Epub 2024 Sep 9. Expert Rev Vaccines. 2024. PMID: 39234779 Free article. Review.
Safety and Immunogenicity of an mRNA-1273 Booster in Children.
Berthaud V, Creech CB, Rostad CA, Carr Q, De Leon L, Dietrich M, Gupta A, Javita D, Nachman S, Pinninti S, Rathore M, Rodriguez CA, Luzuriaga K, Towner W, Yeakey A, Brown M, Zhao X, Deng W, Xu W, Zhou H, Girard B, Kelly R, Slobod K, Anderson EJ, Das R, Miller J, Schnyder Ghamloush S; on behalf the KidCOVE Study Group. Berthaud V, et al. Among authors: yeakey a. Clin Infect Dis. 2024 Aug 19:ciae420. doi: 10.1093/cid/ciae420. Online ahead of print. Clin Infect Dis. 2024. PMID: 39158584
Safety and durability of mRNA-1273-induced SARS-CoV-2 immune responses in adolescents: results from the phase 2/3 TeenCOVE trial.
Figueroa AL, Ali K, Berman G, Zhou H, Deng W, Xu W, Lussier S, Girard B, Dutko FJ, Slobod K, Yeakey A, Priddy F, Miller JM, Das R. Figueroa AL, et al. Among authors: yeakey a. EClinicalMedicine. 2024 Jul 18;74:102720. doi: 10.1016/j.eclinm.2024.102720. eCollection 2024 Aug. EClinicalMedicine. 2024. PMID: 39091673 Free PMC article.
Interim safety and immunogenicity of COVID-19 omicron BA.1 variant-containing vaccine in children in the USA: an open-label non-randomised phase 3 trial.
Dixit A, Bennett R, Ali K, Griffin C, Clifford RA, Turner M, Poston R, Hautzinger K, Yeakey A, Girard B, Zhou W, Deng W, Zhou H, Schnyder Ghamloush S, Kuter BJ, Slobod K, Miller JM, Priddy F, Das R; ROVER Study Investigators. Dixit A, et al. Among authors: yeakey a. Lancet Infect Dis. 2024 Jul;24(7):687-697. doi: 10.1016/S1473-3099(24)00101-4. Epub 2024 Mar 19. Lancet Infect Dis. 2024. PMID: 38518789 Clinical Trial.
Enhanced passive surveillance of influenza vaccination in England, 2016-2017- an observational study using an adverse events reporting card.
de Lusignan S, Ferreira F, Damaso S, Byford R, Pathirannehelage S, Yeakey A, Yonova I, Schuind A, Dos Santos G. de Lusignan S, et al. Among authors: yeakey a. Hum Vaccin Immunother. 2019;15(5):1048-1059. doi: 10.1080/21645515.2019.1565258. Epub 2019 Mar 20. Hum Vaccin Immunother. 2019. PMID: 30648923 Free PMC article.
15 results